Intellectual property is the key to vaccine development, manufacturing and technology sharing
By Megan Van Etten | March 5, 2021
Earlier today, 31 PhRMA board members signed a letter to President Joe Biden applauding the Administration’s accelerating COVID-19 vaccine rollout, but also warning against efforts to undermine...
Read More
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
By Abigail Lore | March 5, 2021
Last week, PhRMA submitted comments to the United States Patent and Trademark Office (USPTO) in response to a request for comments on the National Strategy for Expanding American Innovation....
Read More
How industry collaboration and partnerships are supporting COVID-19 vaccine manufacturing
By Richard Moscicki, M.D. | March 4, 2021
Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 vaccine manufacturing. Companies are working to source needed raw materials and other...
Read More
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
By Katie Koziara | March 2, 2021
A new study published in Health Affairs finds that for nearly 40% of commercially insured patients, half of their annual out-of-pocket expenses for medical treatments come from just one hospital,...
Read More
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
By Stephen J. Ubl | February 24, 2021
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.
Read More
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
By Jocelyn Ulrich | February 22, 2021
As America’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen...
Read More
Fighting variants of COVID-19
By Richard Moscicki, M.D. | February 22, 2021
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop and manufacture safe and effective vaccines. To date, two...
Read More
Key excerpts: PhRMA submits comments to keep the six protected classes protected
By Tom Wilbur | February 19, 2021
Earlier this month, PhRMA submitted comments to CMS regarding the Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This RFA was released on January 19,...
Read More
Top five issues voters want addressed in the administration’s first 100 days
By Mark Keida | February 18, 2021
When voters cast their ballots in the 2020 election, they made clear their focus on getting COVID-19 under control and fixing the economy. However, health care was still important to many voters,...
Read More
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
By Tom Wilbur | February 12, 2021
Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
